Holdings: Radiation oncology advances

Radiation oncology advances:

Saved in:

Bibliographic Details
Format:	Book
Language:	English
Published:	New York, NY Springer 2008
Series:	Cancer treatment and research 139
Subjects:	Cancer > Radiotherapy Neoplasms > radiotherapy Radiotherapy > trends Strahlentherapie Krebs > Medizin
Online Access:	Inhaltsverzeichnis
Physical Description:	XVI, 341 S. Ill., graph. Darst.
ISBN:	9780387367439

Staff View

MARC


LEADER	00000nam a2200000 cb4500
001	BV023040131
003	DE-604
005	20170912
007	t
008	071207s2008 ad\|\| \|\|\|\| 00\|\|\| eng d
020			\|a 9780387367439 \|9 978-0-387-36743-9
035			\|a (OCoLC)209980678
035			\|a (DE-599)BVBBV023040131
040			\|a DE-604 \|b ger \|e rakwb
041	0		\|a eng
049			\|a DE-355 \|a DE-12
050		0	\|a RC271.R3
082	0		\|a 616.9940642 \|2 22
084			\|a XH 3300 \|0 (DE-625)152889:13129 \|2 rvk
245	1	0	\|a Radiation oncology advances \|c ed. by Søren M. Bentzen ...
264		1	\|a New York, NY \|b Springer \|c 2008
300			\|a XVI, 341 S. \|b Ill., graph. Darst.
336			\|b txt \|2 rdacontent
337			\|b n \|2 rdamedia
338			\|b nc \|2 rdacarrier
490	1		\|a Cancer treatment and research \|v 139
650		4	\|a Cancer \|x Radiotherapy
650		4	\|a Neoplasms \|x radiotherapy
650		4	\|a Radiotherapy \|x trends
650	0	7	\|a Strahlentherapie \|0 (DE-588)4057833-1 \|2 gnd \|9 rswk-swf
650	0	7	\|a Krebs \|g Medizin \|0 (DE-588)4073781-0 \|2 gnd \|9 rswk-swf
689	0	0	\|a Krebs \|g Medizin \|0 (DE-588)4073781-0 \|D s
689	0	1	\|a Strahlentherapie \|0 (DE-588)4057833-1 \|D s
689	0		\|C b \|5 DE-604
700	1		\|a Bentzen, Søren M. \|e Sonstige \|4 oth
830		0	\|a Cancer treatment and research \|v 139 \|w (DE-604)BV000001082 \|9 139
856	4	2	\|m Digitalisierung UB Regensburg \|q application/pdf \|u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016243696&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA \|3 Inhaltsverzeichnis
999			\|a oai:aleph.bib-bvb.de:BVB01-016243696

Record in the Search Index

_version_	1804137268324073472
adam_text	Contents 1 Radiation Oncology Advances: An Introduction ..................................... 1 Ѕфгеп M. Bentzen, Paul M. Harari, Wolfgang A. Tomé, and Minesh P. Mehta Advances in Imaging and Theragnostic Radiation Oncology ....................... 1 Advances in Molecular Biology and Targeted Therapies ............................. 2 Advances in Treatment Delivery and Planning ............................................. 3 Clinical Advances .......................................................................................... 4 References ...................................................................................................... 4 Section I. Advances in Imaging and Biologically-Based Treatment Planning 2 Advanced Image-Guided External Beam Radiotherapy ......................... 7 Thomas Rockwell Mackie and Wolfgang Tomé Introduction .................................................................................................... 7 Image Guidance for Defining Target Volumes .......................................... 9 Image Guidance at the Time of Delivery ................................................... 13 Optical Guidance ....................................................................................... 14 Optical Tracking Systems .......................................................................... 15 Optical Tracking in Fractionated Stereotactic Radiotherapy, Intracranial, and Head and Neck IMRT ..................................................... 16 Optically Guided Ultrasound ..................................................................... 18 In-Room CT Guidance ............................................................................... 20 Image Guidance and Organ Motion ........................................................... 27 Image Guidance for Follow-Up Imaging and Retreatments ...................... 29 Summary .................................................................................................... 31 References ...................................................................................................... 32 vi Contents 3 Dose Painting and Theragnostic Imaging: Towards the Prescription, Planning and Delivery of Biologically Targeted Dose Distributions in External Beam Radiation Oncology ......................................................... 41 Ѕфгеп M. Bentzen Radiation Theragnostics .............................................................................. 41 From Anatomical to Biological Targeting in Radiation Therapy ................ 42 From Target Selection and Delineation to 4D Dose Prescription ............... 43 The Case for Nonuniform Theragnostic Dose Distributions ....................... 44 Precision Requirements ............................................................................... 47 Targeting Hypoxia Using EBRT: Are We Ready for Dose Painting by Numbers? .................................................................................. 48 Hypoxia as a Cause of Clinical Failure of Radiation Therapy ................ 48 Hypoxia Imaging ..................................................................................... 50 Spatiotemporal Stability of the PET Hypoxia Map ................................. 53 Dose Painting by Numbers ...................................................................... 56 Dose Delivery and Expected Change in Outcome ................................... 57 Conclusion ................................................................................................... 57 References .................................................................................................... 58 4 Molecular and Functional Imaging in Radiation Oncology .................. 63 Robert Jeraj and M. Elizabeth Meyerand Introduction .................................................................................................. 63 Molecular and Functional Imaging Modalities ........................................... 64 Positron Emission Tomography ............................................................... 64 Single Photon Emission Tomography ...................................................... 65 Dynamic Contrast Enhanced Computer Tomography (DCE-CT) ........... 65 Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) ................................................................................ 65 Magnetic Resonance Spectroscopy .......................................................... 66 Optical Imaging ....................................................................................... 66 Comparison Between Different Imaging Modalities ............................... 66 Molecular and Functional Imaging Targets ................................................. 67 Cellular Metabolism ................................................................................. 68 Cellular Proliferation ............................................................................... 72 Cellular Death .......................................................................................... 73 Cellular Regulation .................................................................................. 74 Tumor Microenvironment........................................................................ 77 Future ........................................................................................................... 80 References .................................................................................................... 82 Contents vii 5 Prognostic and Predictive Markers in Radiation Therapy: Focus on Prostate Cancer ..................................................................................... 97 Mark A. Ritter Introduction .................................................................................................. 97 The Need for Biomarkers of Radiation Response in Prostate Cancer ........................................................................................ 97 Optimal Biomarkers and Patient Cohort Characteristics ............................. 98 Evaluation of Candidate Markers ................................................................ 99 Biological Rationale ................................................................................. 99 Biomarker Frequency ............................................................................... 102 Biomarker Assessment Methods ................................................................. 102 Immunohistochemistry ................................................................................ 103 Clinical Correlative Data in Prostate Cancer ............................................... 104 Markers of Cell Cycle Control, DNA Repair and Apoptosis ................... 105 Proliferation ............................................................................................. 105 Hypoxia .................................................................................................... 106 Limitations of Existing Studies ................................................................... 106 Future Studies and Directions ...................................................................... 107 Large Prospective Clinical Trials ............................................................. 107 Biomarker-Based Adaptive Therapy ........................................................ 108 Conclusion ................................................................................................... 109 References .................................................................................................... 109 Section II. Advances in Molecular Biology and Targeted Therapies 6 Overview of Cancer Molecular Radiobiology ......................................... 117 Jann N. Sarkaria and Robert G. Bristow Introduction .................................................................................................. 117 Interaction of Radiation with Living Cells .................................................. 117 Cellular Response to Ionizing Radiation ..................................................... 118 Cell Cycle Arrest ......................................................................................... 118 DNA Repair ................................................................................................. 120 Apoptosis ..................................................................................................... 121 Cell Survival Signaling ................................................................................ 122 Ras Signaling ........................................................................................... 122 Receptor Tyrosine Kinases ....................................................................... 123 mTOR Signaling ...................................................................................... 123 Targeting Housekeeping Proteins ................................................................ 124 HSP90 Inhibitors ...................................................................................... 125 HDAC Inhibitors ...................................................................................... 126 Proteosome Inhibitors .............................................................................. 128 Conclusion ................................................................................................... 129 References .................................................................................................... 130 viii Contents 7 Clinical Application of EGFR Inhibitors in Head and Neck Squamous Cell Cancer .............................................................................. 135 Igor Astsaturov, Roger B. Cohen, and Paul M. Harari Introduction .................................................................................................. 135 EGFR Biology ............................................................................................. 136 Anti-EGFR Monoclonal Antibodies ............................................................ 138 Radiation Plus Cetuximab For Locoregionally Advanced HNSCC ........ 138 Cetuximab, Cisplatin, and Radiation in Locoregionally Advanced HNSCC ................................................................................... 140 Cetuximab ± Chemotherapy in Recurrent and/or Metastatic HNSCC ....................................................................... 141 Cetuximab with Chemotherapy in the First-Line Treatment of Patients with Recurrent and/or Metastatic HNSCC ............................. 142 EGFR Tyrosine Kinase Inhibitors (TKIs) ................................................... 143 TKI Monotherapy in HNSCC .................................................................. 144 TKIs in Combination with Radiation Therapy ........................................ 144 TKIs with Dual Specificity ...................................................................... 145 Patient Selection ........................................................................................... 145 Conclusions .................................................................................................. 146 References .................................................................................................... 147 8 Advancement of Antiangiogenic and Vascular Disrupting Agents Combined with Radiation ......................................................................... 153 Deborah Citrin and Kevin Camphausen Introduction .................................................................................................. 153 Tumor Vasculature ....................................................................................... 153 Targeting the Tumor Vasculature ................................................................. 155 Antiangiogenic Agents ................................................................................ 155 Vascular Disrupting Agents ......................................................................... 158 Combining Antiangiogenic and Vascular Disrupting Agents with Radiation .............................................................................................. 160 Antiangiogenic Agents and Radiation in the Laboratory ............................ 160 Angiogenesis Inhibitors and Radiation in the Clinic ............................... 162 Vascular Disrupting Agents and Radiation in the Laboratory ................. 163 Vascular Disrupting Agents with Radiation in the Clinic ........................ 164 Future Directions ......................................................................................... 165 Conclusion ................................................................................................... 166 References .................................................................................................... 167 9 Overcoming Therapeutic Resistance in Malignant Gliomas: Current Practices and Future Directions ............................................................... 173 Arnab Chakravarti and Kamalakannan Palanichamy Introduction .................................................................................................. 173 Signal Transduction Pathways Involved in Treatment Resistance .............. 173 Angiogenesis Pathways ............................................................................... 175 Contents ix Conventional Chemotherapeutic Agents in Malignant Gliomas ................. 177 Biotherapeutic Strategies ............................................................................. 182 Antiepidermal Growth Factor Receptor (EGFR) Strategies .................... 182 mTor Pathway Inhibition: CCI-779 ............................................................. 184 Antiangiogenic Strategies ............................................................................ 185 Summary ...................................................................................................... 186 References .................................................................................................... 186 Section III. Advances in Treatment Delivery and Planning 10 Advances in Intensity-Modulated Radiotherapy Delivery .................... 193 John D. Fenwick, Stephen W. Riley, and Alison J.D. Scott Introduction .................................................................................................. 193 Background .................................................................................................. 193 Fixed-Field IMRT ........................................................................................ 194 Direct Aperture Optimisation and Jaws-Only Linear Accelerator IMRT ......................................................................... 199 Tomotherapy ................................................................................................ 199 Axial Tomotherapy .................................................................................. 200 Helical Tomotherapy ................................................................................ 201 Future Developments ............................................................................... 206 CyberKnife ................................................................................................... 208 Summary ...................................................................................................... 209 References .................................................................................................... 210 11 Image-Based Modeling of Normal Tissue Complication Probability for Radiation Therapy ............................................................................... 215 Joseph O. Deasy and Issam El Naqa Introduction .................................................................................................. 215 NTCP Models: Tools or Toys? ................................................................. 216 Why Image-Based NTCP Analysis? ........................................................ 218 Tissue Dose—Response Classification .......................................................... 219 The Concepts of Serial and Parallel Tissue Dose-Response ............ 219 Local vs. Global Organ Injuries ............................................................... 221 NTCP Models .............................................................................................. 222 The Generalized Equivalent Uniform Dose Equation ............................. 223 Basic Mathematical Features of Common NTCP Functions ................... 225 Cluster Models ......................................................................................... 227 A Data-Mining/Data-Driven Approach to NTCP Modeling ................... 227 Selection of Relevant Input Variables ...................................................... 231 Selection of Model Functional Form ........................................................... 232 Selection of Model Order ............................................................................ 233 Model Order Based on Information Theory ............................................ 233 Model Order Based on Cross-validation Methods ................................... 235 Model Variable Stability .......................................................................... 235 x Contents Model Parameter Fitting .......................................................................... 235 Image-Based Factors and Radiosensitivity Predictors ............................. 236 Some Critical NTCP Endpoints................................................................... 237 Late Rectal Toxicity Due to External Beam Prostate Cancer Treatment ..................................................................................... 237 Radiation Pneumonitis Due to Thoracic Irradiation for Lung Cancer ............................................................................................. 238 Xerostomia Due to Head and Neck Cancer Treatment ............................ 240 Drawbacks to Treatment Planning Based on Dose-Volume Limits ........ 243 Uncertainties in NTCP Models ................................................................ 244 Incorporating Fractionation Sensitivity ................................................... 245 Summary ...................................................................................................... 248 References .................................................................................................... 248 12 Optimization of Radiotherapy Using Biological Parameters ................ 257 Yusung Kim and Wolfgang Tomé Introduction .................................................................................................. 257 The Need for Optimization Based on Biological Parameters .................. 259 Radiobiological Models ........................................................................... 260 Biological Optimization ............................................................................... 264 Subvolume-Based Radiobiological Models ............................................. 264 Impact of Diagnostic Accuracy on Biological Optimization ...................... 270 Functional Imaging in Oncology ............................................................. 270 Theragnostic Imaging in Risk-Adaptive Radiotherapy ............................ 270 The Impact of Imaging Sensitivity on Risk-Adaptive Radiotherapy ....... 271 Clinical Parameters Necessary for Biological Optimization ................... 272 Summary ...................................................................................................... 274 References .................................................................................................... 275 Section IV. Clinical Advances 13 Combined Chemoradiotherapy Advances ............................................... 281 Gordon Wong and Minesh P. Mehta Introduction .................................................................................................. 281 Head and Neck Cancers ............................................................................... 282 Nonsmall Cell Lung Carcinoma .................................................................. 288 Cervical Carcinoma ..................................................................................... 292 Esophageal Carcinoma ................................................................................ 294 Rectal Adenocarcinoma ............................................................................... 296 Anal Squamous Cell Carcinoma .................................................................. 298 Muscle Invasive Bladder Cancer ................................................................. 299 Conclusion ................................................................................................... 300 References .................................................................................................... 300 Contents xi 14 Cytoprotection for Radiation-Associated Normal Tissue Injury ............................................................................................... 307 Jingfang Mao, Oluwatoyosi A. Fatunase, and Lawrence B. Marks Biologic Rationale of Cytoprotectors .......................................................... 307 Assessment of Amifostine in Patients with Head and Neck Cancer ........... 309 Assessment of Amifostine in Patients with Thoracic Tumors .................... 309 Lung Injury .............................................................................................. 309 Esophageal Injury .................................................................................... 312 Assessment of Amifostine in Patients with Pelvic Tumors ......................... 312 Assessment of Amifostine in Patients with Tumors at Other Sites ............. 312 Impact of Amifostine on Tumor Control and Survival ............................... 314 Amifostine-Related Toxicity ........................................................................ 314 Administration of Amifostine ...................................................................... 314 Other Cytoprotectors .................................................................................... 321 Conclusion ................................................................................................... 323 References .................................................................................................... 323 Index .................................................................................................................. 329
adam_txt	Contents 1 Radiation Oncology Advances: An Introduction . 1 Ѕфгеп M. Bentzen, Paul M. Harari, Wolfgang A. Tomé, and Minesh P. Mehta Advances in Imaging and Theragnostic Radiation Oncology . 1 Advances in Molecular Biology and Targeted Therapies . 2 Advances in Treatment Delivery and Planning . 3 Clinical Advances . 4 References . 4 Section I. Advances in Imaging and Biologically-Based Treatment Planning 2 Advanced Image-Guided External Beam Radiotherapy . 7 Thomas Rockwell Mackie and Wolfgang Tomé Introduction . 7 Image Guidance for Defining Target Volumes . 9 Image Guidance at the Time of Delivery . 13 Optical Guidance . 14 Optical Tracking Systems . 15 Optical Tracking in Fractionated Stereotactic Radiotherapy, Intracranial, and Head and Neck IMRT . 16 Optically Guided Ultrasound . 18 In-Room CT Guidance . 20 Image Guidance and Organ Motion . 27 Image Guidance for Follow-Up Imaging and Retreatments . 29 Summary . 31 References . 32 vi Contents 3 Dose Painting and Theragnostic Imaging: Towards the Prescription, Planning and Delivery of Biologically Targeted Dose Distributions in External Beam Radiation Oncology . 41 Ѕфгеп M. Bentzen Radiation Theragnostics . 41 From Anatomical to Biological Targeting in Radiation Therapy . 42 From Target Selection and Delineation to 4D Dose Prescription . 43 The Case for Nonuniform Theragnostic Dose Distributions . 44 Precision Requirements . 47 Targeting Hypoxia Using EBRT: Are We Ready for Dose Painting by Numbers? . 48 Hypoxia as a Cause of Clinical Failure of Radiation Therapy . 48 Hypoxia Imaging . 50 Spatiotemporal Stability of the PET Hypoxia Map . 53 Dose Painting by Numbers . 56 Dose Delivery and Expected Change in Outcome . 57 Conclusion . 57 References . 58 4 Molecular and Functional Imaging in Radiation Oncology . 63 Robert Jeraj and M. Elizabeth Meyerand Introduction . 63 Molecular and Functional Imaging Modalities . 64 Positron Emission Tomography . 64 Single Photon Emission Tomography . 65 Dynamic Contrast Enhanced Computer Tomography (DCE-CT) . 65 Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) . 65 Magnetic Resonance Spectroscopy . 66 Optical Imaging . 66 Comparison Between Different Imaging Modalities . 66 Molecular and Functional Imaging Targets . 67 Cellular Metabolism . 68 Cellular Proliferation . 72 Cellular Death . 73 Cellular Regulation . 74 Tumor Microenvironment. 77 Future . 80 References . 82 Contents vii 5 Prognostic and Predictive Markers in Radiation Therapy: Focus on Prostate Cancer . 97 Mark A. Ritter Introduction . 97 The Need for Biomarkers of Radiation Response in Prostate Cancer . 97 Optimal Biomarkers and Patient Cohort Characteristics . 98 Evaluation of Candidate Markers . 99 Biological Rationale . 99 Biomarker Frequency . 102 Biomarker Assessment Methods . 102 Immunohistochemistry . 103 Clinical Correlative Data in Prostate Cancer . 104 Markers of Cell Cycle Control, DNA Repair and Apoptosis . 105 Proliferation . 105 Hypoxia . 106 Limitations of Existing Studies . 106 Future Studies and Directions . 107 Large Prospective Clinical Trials . 107 Biomarker-Based Adaptive Therapy . 108 Conclusion . 109 References . 109 Section II. Advances in Molecular Biology and Targeted Therapies 6 Overview of Cancer Molecular Radiobiology . 117 Jann N. Sarkaria and Robert G. Bristow Introduction . 117 Interaction of Radiation with Living Cells . 117 Cellular Response to Ionizing Radiation . 118 Cell Cycle Arrest . 118 DNA Repair . 120 Apoptosis . 121 Cell Survival Signaling . 122 Ras Signaling . 122 Receptor Tyrosine Kinases . 123 mTOR Signaling . 123 Targeting Housekeeping Proteins . 124 HSP90 Inhibitors . 125 HDAC Inhibitors . 126 Proteosome Inhibitors . 128 Conclusion . 129 References . 130 viii Contents 7 Clinical Application of EGFR Inhibitors in Head and Neck Squamous Cell Cancer . 135 Igor Astsaturov, Roger B. Cohen, and Paul M. Harari Introduction . 135 EGFR Biology . 136 Anti-EGFR Monoclonal Antibodies . 138 Radiation Plus Cetuximab For Locoregionally Advanced HNSCC . 138 Cetuximab, Cisplatin, and Radiation in Locoregionally Advanced HNSCC . 140 Cetuximab ± Chemotherapy in Recurrent and/or Metastatic HNSCC . 141 Cetuximab with Chemotherapy in the First-Line Treatment of Patients with Recurrent and/or Metastatic HNSCC . 142 EGFR Tyrosine Kinase Inhibitors (TKIs) . 143 TKI Monotherapy in HNSCC . 144 TKIs in Combination with Radiation Therapy . 144 TKIs with Dual Specificity . 145 Patient Selection . 145 Conclusions . 146 References . 147 8 Advancement of Antiangiogenic and Vascular Disrupting Agents Combined with Radiation . 153 Deborah Citrin and Kevin Camphausen Introduction . 153 Tumor Vasculature . 153 Targeting the Tumor Vasculature . 155 Antiangiogenic Agents . 155 Vascular Disrupting Agents . 158 Combining Antiangiogenic and Vascular Disrupting Agents with Radiation . 160 Antiangiogenic Agents and Radiation in the Laboratory . 160 Angiogenesis Inhibitors and Radiation in the Clinic . 162 Vascular Disrupting Agents and Radiation in the Laboratory . 163 Vascular Disrupting Agents with Radiation in the Clinic . 164 Future Directions . 165 Conclusion . 166 References . 167 9 Overcoming Therapeutic Resistance in Malignant Gliomas: Current Practices and Future Directions . 173 Arnab Chakravarti and Kamalakannan Palanichamy Introduction . 173 Signal Transduction Pathways Involved in Treatment Resistance . 173 Angiogenesis Pathways . 175 Contents ix Conventional Chemotherapeutic Agents in Malignant Gliomas . 177 Biotherapeutic Strategies . 182 Antiepidermal Growth Factor Receptor (EGFR) Strategies . 182 mTor Pathway Inhibition: CCI-779 . 184 Antiangiogenic Strategies . 185 Summary . 186 References . 186 Section III. Advances in Treatment Delivery and Planning 10 Advances in Intensity-Modulated Radiotherapy Delivery . 193 John D. Fenwick, Stephen W. Riley, and Alison J.D. Scott Introduction . 193 Background . 193 Fixed-Field IMRT . 194 Direct Aperture Optimisation and Jaws-Only Linear Accelerator IMRT . 199 Tomotherapy . 199 Axial Tomotherapy . 200 Helical Tomotherapy . 201 Future Developments . 206 CyberKnife . 208 Summary . 209 References . 210 11 Image-Based Modeling of Normal Tissue Complication Probability for Radiation Therapy . 215 Joseph O. Deasy and Issam El Naqa Introduction . 215 NTCP Models: Tools or Toys? . 216 Why Image-Based NTCP Analysis? . 218 Tissue Dose—Response Classification . 219 The Concepts of "Serial" and "Parallel" Tissue Dose-Response . 219 Local vs. Global Organ Injuries . 221 NTCP Models . 222 The Generalized Equivalent Uniform Dose Equation . 223 Basic Mathematical Features of Common NTCP Functions . 225 Cluster Models . 227 A Data-Mining/Data-Driven Approach to NTCP Modeling . 227 Selection of Relevant Input Variables . 231 Selection of Model Functional Form . 232 Selection of Model Order . 233 Model Order Based on Information Theory . 233 Model Order Based on Cross-validation Methods . 235 Model Variable Stability . 235 x Contents Model Parameter Fitting . 235 Image-Based Factors and Radiosensitivity Predictors . 236 Some Critical NTCP Endpoints. 237 Late Rectal Toxicity Due to External Beam Prostate Cancer Treatment . 237 Radiation Pneumonitis Due to Thoracic Irradiation for Lung Cancer . 238 Xerostomia Due to Head and Neck Cancer Treatment . 240 Drawbacks to Treatment Planning Based on Dose-Volume Limits . 243 Uncertainties in NTCP Models . 244 Incorporating Fractionation Sensitivity . 245 Summary . 248 References . 248 12 Optimization of Radiotherapy Using Biological Parameters . 257 Yusung Kim and Wolfgang Tomé Introduction . 257 The Need for Optimization Based on Biological Parameters . 259 Radiobiological Models . 260 Biological Optimization . 264 Subvolume-Based Radiobiological Models . 264 Impact of Diagnostic Accuracy on Biological Optimization . 270 Functional Imaging in Oncology . 270 Theragnostic Imaging in Risk-Adaptive Radiotherapy . 270 The Impact of Imaging Sensitivity on Risk-Adaptive Radiotherapy . 271 Clinical Parameters Necessary for Biological Optimization . 272 Summary . 274 References . 275 Section IV. Clinical Advances 13 Combined Chemoradiotherapy Advances . 281 Gordon Wong and Minesh P. Mehta Introduction . 281 Head and Neck Cancers . 282 Nonsmall Cell Lung Carcinoma . 288 Cervical Carcinoma . 292 Esophageal Carcinoma . 294 Rectal Adenocarcinoma . 296 Anal Squamous Cell Carcinoma . 298 Muscle Invasive Bladder Cancer . 299 Conclusion . 300 References . 300 Contents xi 14 Cytoprotection for Radiation-Associated Normal Tissue Injury . 307 Jingfang Mao, Oluwatoyosi A. Fatunase, and Lawrence B. Marks Biologic Rationale of Cytoprotectors . 307 Assessment of Amifostine in Patients with Head and Neck Cancer . 309 Assessment of Amifostine in Patients with Thoracic Tumors . 309 Lung Injury . 309 Esophageal Injury . 312 Assessment of Amifostine in Patients with Pelvic Tumors . 312 Assessment of Amifostine in Patients with Tumors at Other Sites . 312 Impact of Amifostine on Tumor Control and Survival . 314 Amifostine-Related Toxicity . 314 Administration of Amifostine . 314 Other Cytoprotectors . 321 Conclusion . 323 References . 323 Index . 329
any_adam_object	1
any_adam_object_boolean	1
building	Verbundindex
bvnumber	BV023040131
callnumber-first	R - Medicine
callnumber-label	RC271
callnumber-raw	RC271.R3
callnumber-search	RC271.R3
callnumber-sort	RC 3271 R3
callnumber-subject	RC - Internal Medicine
classification_rvk	XH 3300
ctrlnum	(OCoLC)209980678 (DE-599)BVBBV023040131
dewey-full	616.9940642
dewey-hundreds	600 - Technology (Applied sciences)
dewey-ones	616 - Diseases
dewey-raw	616.9940642
dewey-search	616.9940642
dewey-sort	3616.9940642
dewey-tens	610 - Medicine and health
discipline	Medizin
discipline_str_mv	Medizin
format	Book
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01605nam a2200421 cb4500</leader><controlfield tag="001">BV023040131</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20170912 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">071207s2008 ad\|\| \|\|\|\| 00\|\|\| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780387367439</subfield><subfield code="9">978-0-387-36743-9</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)209980678</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV023040131</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-12</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC271.R3</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.9940642</subfield><subfield code="2">22</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 3300</subfield><subfield code="0">(DE-625)152889:13129</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Radiation oncology advances</subfield><subfield code="c">ed. by Søren M. Bentzen ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York, NY</subfield><subfield code="b">Springer</subfield><subfield code="c">2008</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XVI, 341 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Cancer treatment and research</subfield><subfield code="v">139</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield><subfield code="x">Radiotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms</subfield><subfield code="x">radiotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Radiotherapy</subfield><subfield code="x">trends</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Strahlentherapie</subfield><subfield code="0">(DE-588)4057833-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Strahlentherapie</subfield><subfield code="0">(DE-588)4057833-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="C">b</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bentzen, Søren M.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Cancer treatment and research</subfield><subfield code="v">139</subfield><subfield code="w">(DE-604)BV000001082</subfield><subfield code="9">139</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016243696&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-016243696</subfield></datafield></record></collection>
id	DE-604.BV023040131
illustrated	Illustrated
index_date	2024-07-02T19:20:19Z
indexdate	2024-07-09T21:09:36Z
institution	BVB
isbn	9780387367439
language	English
oai_aleph_id	oai:aleph.bib-bvb.de:BVB01-016243696
oclc_num	209980678
open_access_boolean
owner	DE-355 DE-BY-UBR DE-12
owner_facet	DE-355 DE-BY-UBR DE-12
physical	XVI, 341 S. Ill., graph. Darst.
publishDate	2008
publishDateSearch	2008
publishDateSort	2008
publisher	Springer
record_format	marc
series	Cancer treatment and research
series2	Cancer treatment and research
spelling	Radiation oncology advances ed. by Søren M. Bentzen ... New York, NY Springer 2008 XVI, 341 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Cancer treatment and research 139 Cancer Radiotherapy Neoplasms radiotherapy Radiotherapy trends Strahlentherapie (DE-588)4057833-1 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 s Strahlentherapie (DE-588)4057833-1 s b DE-604 Bentzen, Søren M. Sonstige oth Cancer treatment and research 139 (DE-604)BV000001082 139 Digitalisierung UB Regensburg application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016243696&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis
spellingShingle	Radiation oncology advances Cancer treatment and research Cancer Radiotherapy Neoplasms radiotherapy Radiotherapy trends Strahlentherapie (DE-588)4057833-1 gnd Krebs Medizin (DE-588)4073781-0 gnd
subject_GND	(DE-588)4057833-1 (DE-588)4073781-0
title	Radiation oncology advances
title_auth	Radiation oncology advances
title_exact_search	Radiation oncology advances
title_exact_search_txtP	Radiation oncology advances
title_full	Radiation oncology advances ed. by Søren M. Bentzen ...
title_fullStr	Radiation oncology advances ed. by Søren M. Bentzen ...
title_full_unstemmed	Radiation oncology advances ed. by Søren M. Bentzen ...
title_short	Radiation oncology advances
title_sort	radiation oncology advances
topic	Cancer Radiotherapy Neoplasms radiotherapy Radiotherapy trends Strahlentherapie (DE-588)4057833-1 gnd Krebs Medizin (DE-588)4073781-0 gnd
topic_facet	Cancer Radiotherapy Neoplasms radiotherapy Radiotherapy trends Strahlentherapie Krebs Medizin
url	http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016243696&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA
volume_link	(DE-604)BV000001082
work_keys_str_mv	AT bentzensørenm radiationoncologyadvances

Holdings

There is no print copy available.

Interlibrary loan Place Request Caution: Not in THWS collection! Indexes

MARC

Record in the Search Index

There is no print copy available.

Similar Items